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Research
Humans and wildlife are exposed to a vari-
ety of contaminants, such as xeno  estrogens, 
on a daily basis. Bisphenol A (BPA), a xeno-
estrogen, is a constituent of poly  carbonate 
plastics and epoxy resins used in dentistry 
and in the food industry. The polymer bonds 
hydrolyze at high temperatures and release 
BPA. BPA could be ingested by humans; 
detectable amounts have been found in food 
cans, microwave containers, poly  carbonate 
bottles, and in human saliva after treatment 
with dental sealants (Vandenberg et al. 2007). 
Although results of some in vitro assays have 
suggested that BPA is a weak environmental 
estrogen (Vandenberg et al. 2007; Wetherill 
et al. 2007), important in vivo effects have 
been found using a wide range of doses, ani-
mal models, and study end points. The cur-
rent U.S. Environmental Protection Agency 
(EPA) reference dose [50 µg/kg/day (U.S. EPA 
1993)] was calculated by dividing the lowest 
observed adverse effect level (LOAEL; 50 mg/
kg/day) by 1,000. For the present study, 
we defined low doses as those < LOAEL, 
as reported by Richter et al. (2007). Effects 
of BPA can be influenced by species, strain, 
dose, and time of exposure. Adult animals 
exposed to BPA show effects that are revers-
ible when the exposure ceases (Richter et al. 
2007). In contrast, perinatal or neonatal 
exposure produces organizational effects that 
are irreversible in Sprague-Dawley (Kato et al. 
2003; Moral et al. 2008; Patisaul et al. 2006; 
Rubin et al. 2001), Wistar (Durando et al. 
2007; Ramos et al. 2003), and Fisher 344 rats 
(Khurana et al. 2000). These permanent effects 
are in agreement with the actions of estrogens 
during development, ranging from the estab-
lishment of sex differences to pervasive trophic 
and neuro  protective effects (McCarthy 2008).
In addition to its estrogenicity, BPA can 
antagonize the effects of estrogens, androgens, 
or thyroid hormones; act through non-genomic 
pathways; and influence enzyme activity or 
receptor expression (Wetherill et al. 2007). 
Gonadotropin-releasing hormone (GnRH) 
is a hypothalamic decapeptide critical for 
normal mammalian reproductive function. 
GnRH secretion is pulsatile and acts on 
gonado  tropes to stimulate synthesis and release 
of luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) (Pawson et al. 
2005). Gonadotropins are composed of an 
alpha subunit, common to both, and beta sub-
units, unique for each of them. The frequency 
of the GnRH pulses determines the predomi-
nant subunit transcribed at a given time. LHβ 
is transcribed at fast GnRH pulses, whereas 
FSHβ is favored at slow pulse frequencies 
(Ferris and Shupnik 2006). 
After binding of GnRH to its receptor 
(a Gq/11-coupled receptor), phospholipase C 
is activated, leading to diacylglycerol and 
inositol 1,4,5-triphosphate (IP3) formation 
(Naor et al. 1986). Subsequently, IP3 induces 
an increase of intracellular calcium (leading 
to gonadotropin release) and protein kinase 
C (PKC) is activated, resulting in multiple 
cellu  lar responses, such as activation of the 
mitogen-activated protein kinase (MAPK) 
family (Sundaresan et al. 1996). 
In this study we explored the effects of neo-
natal exposure to high and low doses of BPA 
on reproductive parameters in female Sprague-
Dawley rats, a strain reported to have low sen-
sitivity to estrogenic compounds (Steinmetz 
et al. 1997). We analyzed puberty onset, 
estrous cyclicity, in vivo and in vitro pituitary 
response to GnRH, GnRH pulsatility, and 
GnRH-activated signaling pathways. 
Materials and Methods
Animals. Studies were performed accord-
ing to protocols for animal use (Institute of 
Laboratory Animal Resources 1996) and 
approved by the institutional animal care and 
use committee of the Instituto de Biología y 
Medicina Experimental, Consejo Nacional de 
Investigaciones Científicas y Técnicas (IByME-
CONICET). Animals were treated humanely 
and with regard for alleviation of suffering.
Sprague-Dawley rats (200–250 g) from 
the IByME colony, established from Charles 
River stock in 1985, were maintained under 
a controlled 12-hr light/dark cycle and tem-
perature conditions. They were housed in steel 
cages with wood shavings as bedding material 
and given free access to commercial laboratory 
chow (Gepsa Feeds, Grupo Pilar S.A, Córdoba, 
Argentina) and tap water in glass bottles. We 
did not test the phytoestrogen concentration in 
the food, but we assumed that all animals were 
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Ba c k g r o u n d: Bisphenol A (BPA) is a component of polycarbonate plastics, epoxy resins, and poly-
styrene and is found in many products. Several reports have revealed potent in vivo effects, because BPA 
acts as an estrogen agonist and/or antagonist and as an androgen and thyroid hormone antagonist.
oBjectives: We analyzed the effects of neonatal exposure to BPA on the reproductive axis of female 
Sprague-Dawley rats. 
Me t h o d s : Female rats were injected subcutaneusly, daily, from postnatal day 1 (PND1) to PND10 
with BPA [500 µg/50 µL (high) or 50 µg/50 µL (low)] in castor oil or with castor oil vehicle alone. 
We studied body weight and age at vaginal opening, estrous cycles, and pitui  tary hormone release 
in vivo and in vitro, as well as gonadotropin-releasing hormone (GnRH) pulsatility at PND13 and in 
adults. We also analyzed two GnRH-activated signaling pathways in the adults: inositol-triphosphate 
(IP3), and extracellular signal-regulated kinase 1/2 (ERK1/2). 
re s u l t s: Exposure to BPA altered pituitary function in infantile rats, lowering basal and GnRH-
induced luteinizing hormone (LH) and increasing GnRH pulsatility. BPA dose-dependently accel-
erated puberty onset and altered estrous cyclicity, with the high dose causing permanent estrus. In 
adults treated neonatally with BPA, GnRH-induced LH secretion in vivo was decreased and GnRH 
pulsatility remained disrupted. In vitro, pituitary cells from animals treated with BPA showed lower 
basal LH and dose-dependently affected GnRH-induced IP3 formation; the high dose also impaired 
GnRH-induced LH secretion. Both doses altered ERK1/2 activation.
co n c l u s i o n s: Neonatal exposure to BPA altered reproductive parameters and hypothalamic–
pituitary function in female rats. To our knowledge, these results demonstrate for the first time that 
neonatal in vivo BPA permanently affects GnRH pulsatility and pituitary GnRH signaling.
key w o r d s : Bisphenol A, estrous cycle, GnRH pulsatility, GnRH signaling, gonadotropins, 
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exposed to the same levels, since food intake 
was equivalent between groups.
Pregnant females were housed indi-
vidually; on the day of birth [postnatal day 
(PND) 1], litters were reduced to eight pups. 
Female neonates from each litter were assigned 
to the different experimental groups and left 
with the dam. On PND1–PND10, each 
pup received a daily sub  cutaneous injection 
of BPA (Aldrich, Milwaukee, WI, USA) in 
castor oil [50 µg/50 µL (BPA50; dose range: 
6.2–2.5 mg/kg body weight); 500 µg/50 µL 
(BPA500; 62.5–25.0 mg/kg)] or castor oil 
vehicle (control). BPA500 has been used previ-
ously in this and other strains of rats (Khurana 
et al. 2000; Patisaul et al. 2006, 2007); because 
it is slightly > LOAEL, we consider it to be a 
high dose. We consider 50 µg/50 µL BPA to 
be a low dose because it is below the LOAEL.
First experimental design. On PND13, an 
age in which the pituitary is highly sensitive 
to stimu  latory and inhibitory inputs (Becu-
Villalobos et al. 1990), animals treated with 
vehicle (control), BPA50, or BPA500 on 
PND1–10 were killed and trunk blood was 
collected. We then determined serum prolactin 
(PRL) by radioimmuno  assay (RIA).
In vivo GnRH-induced gonadotropin 
release. On PND13, we injected 9–12 animals 
from each group intraperitoneally with 100 ng 
GnRH (Bachem, Torrance, CA, USA) or 
saline solution. After 15 min (LH) or 50 min 
(FSH), trunk blood was collected; serum LH 
and FSH were then determined by RIA. 
GnRH pulsatility. We performed pulsatil-
ity studies ex vivo as described by Heger et al. 
(2003). Briefly, On PND13, preoptic area-
anterior hypothalamus–medial basal hypo-
thalamus (POA-MBH) were collected and 
incubated in 1.5 mL microfuge tubes contain-
ing 250 µL Krebs-Ringer bicarbonate buffer 
with 4.5 mg/mL glucose and 16 mM HEPES 
at 37°C for 6 hr. After 30 min pre  incubation, 
the medium from each flask was renewed at 
9-min intervals; medium was stored (–20°C) 
for GnRH measurement by RIA.
We identified GnRH pulses and defined 
their parameters using Cluster8 computer 
algorithm analysis developed by Veldhuis 
and Johnson (1986) and obtained from 
M.L. Johnson (University of Virginia; avail-
able: http://mljohnson.pharm.virginia.edu/
home.html). We used a 2 × 2 cluster configu-
ration and a t statistic of 2 for the upstroke 
and downstroke to maintain false-positive and 
false-negative error rates < 10%, as suggested 
by Martinez de la Escalera et al. (1992). The 
experiment was repeated four times, including 
one animal from each group per experiment.
In vitro GnRH-induced gonadotropin 
release. Using high-dose animals and controls 
on PDN13, we obtained anterior pituitary 
cells as described by Mongiat et al. (2006); 
we used three pituitaries from each group for 
each culture. Cells were plated (50,000 cells/
well) in complete medium; after 5 days, they 
were washed with serum-free medium (SFM) 
and stimulated with GnRH 1.10–9 M and 
1.10–7 M (1 hr). Media were stored (–20°C) 
for gonadotropin analysis by RIA. The experi-
ment was performed in quad  ruplicate (n = 7 
per treatment group). 
Second experimental design. After wean-
ing on PND21, 11–15 pups from each treat-
ment group (control, BPA50, and BPA500) 
were weighed daily and the age and weight at 
vaginal opening (VO) were recorded. Animals 
were multiple-housed (four per cage), keeping 
members of each litter together. We deter-
mined estrous cycles in five animals from each 
group from PND60 to PND120 by examin-
ing vaginal smears under a light microscope. 
After PND120, serum hormones, pitui  tary 
response to GnRH, and GnRH pulsatility 
were determined in animals in estrus.
In vivo GnRH-induced gonadotropin 
release. For this experiment we used seven adult 
animals from each treatment group. Under   
ketamine/xylazine anesthesia (60/10 mg/kg 
body weight), one blood sample was collected 
from the jugular vein (0 min) and GnRH 
(100 ng) was administered into the same vein. 
Further samples were taken at 15 and 50 min. 
Serum LH was determined by RIA.
GnRH pulsatility. Experiments and analy-
sis were performed as described above (n = 7). 
Inositol phosphate determination. Levels 
of inositol mono  phosphate (IP1), biphosphate 
(IP2), and IP3 were meas  ured as described 
by Mongiat et al. (2004). Pituitary cells 
from adult animals in each treatment group 
were plated (500,000 cells/well) in complete 
medium, with two pitui  taries from each experi-
mental group used per culture. After 4 days, 
cells were incubated for 48 hr with 4 µCi/mL/
well of [2-3H(N)]-myo-inositol (PerkinElmer 
Life Sciences, Wallac Oy, Turku, Finland), 
washed with SFM, and incubated for 15 min 
in the presence of 20 mM lithium chlo-
ride. Stimuli were added [final concentra-
tions: GnRH, 1.10–7 M; GnRH-antagonist 
Cetrorelix (CRX), 1.10–6 M (Serono, Buenos 
Aires, Argentina)], and cells were incubated for 
30 min. After incubation, media were collected 
to meas  ure LH, and cells were scraped in 0.5% 
perchloric acid; lysates were then transferred 
to microfuge tubes, neutralized with 0.72 M 
potassium hydroxide and 0.6 M potassium 
bicarbonate, and centrifuged for 10 min at 
3,000 rpm. Supernatants were chromato-
graphed in ionic exchange columns (Dowex 
AG1-XP Resin, 200–400 mesh, formate form; 
Bio-Rad Laboratories, Hercules, CA, USA) to 
elute free inositol, IP1, IP2, and IP3. Aliquots 
of the eluates were mixed with OptiPhase 
‘‘Hisafe’’ 3 (PerkinElmer) and counted in a liq-
uid scintillation counter; results are expressed 
as IP3/inositol (n = 6 per treatment group).
GnRH-induced activation of extra  cellular 
signal-regulated kinase1/2 (ERK1/2). We deter-
mined ERK1/2 activation by Western blot 
analy  sis (Chamson-Reig et al. 2003). Pituitary 
cells from adult animals were plated (250,000 
cells/well) as described previously, using one 
pituitary from each treatment group per cul-
ture. After 5 days, cells were washed with 
SFM and stimu  lated for 0, 5, 15, or 30 min 
with GnRH (1.10–7 M). Media were then 
removed and sample buffer (80 µL) added to 
the wells; plates were stored at –70°C. Cell 
lysates (20 µL) were run on 12% SDS-PAGE 
gels (Bio-Rad) and electro  transferred to nitro-
cellulose membranes, which were then blocked 
with 5% BSA–0.1% Tween-phosphate buff-
ered saline (TPBS) for 2 hr at room tempera-
ture (RT). Membranes were incubated with 
a mouse phospho-specific ERK1/2 antibody 
(pERK1/2, sc-7383, 1:1,500; Santa Cruz 
Biotechnology) for 2 hr at RT. Membranes 
were stripped, blocked with 3% fat-free milk–
TPBS buffer (1 hr at RT), and probed for 1 hr 
at RT with a rabbit polyclonal antibody that 
detects total ERK1/2 (sc-94, 1:1200; Santa Cruz 
Biotechnology). Signals were detected with 
horseradish peroxidase-conjugated anti-mouse 
antibody (1:2000, 1 hr at RT) or anti-rabbit 
antibody (1:4000, 2 hr at RT) and visualized 
by chemiluminescence. Immunoblots were 
quantified using Scion Image Software (Scion 
Corporation, Frederick, MD, USA); results are 
expressed as pERK1/2/total ERK1/2 (n = 4 per 
treatment group).
Hormone dosage. We determined hor-
mones by RIA using kits obtained from the 
National Hormone and Peptide Program 
(Torrance, CA, USA). Results are expressed 
in terms of reference preparation 3 rat LH, 
FSH, and PRL standards. Assay sensitivities 
were 0.015 ng/mL for LH, 0.1175 ng/mL 
for FSH, and 0.04 ng/mL for PRL. Intra  assay 
and inter  assay coefficients of varia  tion, respec-
tively, were as follows: LH, 7.2% and 11.4%; 
FSH, 8.0% and 13.2%; and PRL, 8.1% and 
11.4%. We performed the GnRH RIA as 
described by Mongiat et al. (2006); assay sen-
sitivity was 1.5 pg, and intra  assay and inter-
assay coefficients of variation were 7.1% and 
11.6%, respectively.
Statistical analysis. We analyzed hormonal 
levels in PND13 and adult animals, pulsatility 
and puberty parameters, and estrous cycles 
by one-way or two-way analysis of variance 
(ANOVA) using Statistica, version 5, software 
(StatSoft Inc., Tulsa, OK, USA).We analyzed 
GnRH-induced LH in adults, IP3/inositol, 
Western blots, and LH and FSH released to 
culture media by repeated measures two-way 
ANOVA (Statistica, version 5). Data were 
transformed when the test for homogeneity 
of variances so required. Results are expressed 
as mean ± SE, and p < 0.05 is considered   
significant.Environmental Health Perspectives  •  v o l u m e  117 | n u m b e r 5 | May 2009  759
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Results
Effects of neonatal BPA exposure on basal and 
GnRH-stimulated gonadotropin secretion and 
on GnRH pulsatility in infantile female rats. 
On PND13, BPA500-treated animals had 
significantly lower basal serum LH than did 
controls [mean ± SE: control, 2.44 ± 0.28 ng/
mL (n = 11); BPA50, 1.89 ± 0.18 ng/mL 
(n = 9); BPA500, 1.57 ± 0.18 ng/mL (n = 11); 
control vs. BPA500, p < 0.05]. GnRH signifi-
cantly increased serum LH in all groups, but 
exposure to BPA dose dependently lowered 
GnRH-induced LH release, reaching statisti-
cal significance at the higher dose (Figure 1). 
However, the stimulated to basal ratio was not 
different among groups [GnRH-stimulated 
LH (fold increase), mean ± SE: control, 
18.10 ± 3.01; BPA50, 17.00 ± 1.80; BPA500, 
16.23 ± 2.50; not significant]. We observed 
no differences in either basal or GnRH-
stimulated FSH levels (data not shown). 
Next, we evaluated the response to 
GnRH in pituitary cells from control and 
high-dose animals cultured in vitro, a situ-
ation in which cells were deprived from 
the regulatory inputs from the gonads and 
the brain. Pituitary cells from the BPA500 
group released significantly less LH to the 
media than controls, basally and after GnRH 
(1.10–9 M and 1.10–7 M) stimulation, similar 
to the in vivo results. For 1.10–7 M GnRH, 
LH concentrations were as follows: for con-
trol, 17.37 ± 1.66 ng/50,000 cells for basal 
and 46.75 ± 7.81 ng/50,000 cells for GnRH; 
for BPA500, 7.67 ± 0.87 ng/50,000 cells for 
basal and 24.43 ± 4.08 ng/50,000 cells for 
GnRH (n = 7; control vs. BPA500, p < 0.05). 
Again, percent increases were similar between 
groups for LH; after 1.10–7 M GnRH, per-
cent increases were 277.4 ± 56.3% for control 
and 334.3 ± 68.0% for BPA500 (not signifi-
cant). We observed no differences in basal or 
GnRH-induced FSH levels between groups 
(data not shown).
In GnRH pulsatility studies, both BPA-
treated groups exhibited significantly higher 
pulse frequency than controls, as well as an 
increased number of peaks per hour and a 
reduced interpulse interval (Figure 2A, B). 
Representative profiles of pulsatile GnRH 
release are shown in Figure 2C. We found no 
differences in the area under the concentration 
curve among treatments (data not shown).
Because we found differences in GnRH 
pulsatility with these two BPA doses, we car-
ried out another experiment using hypotha-
lami from animals injected as before but with 
a 10-fold lower dose of BPA (5 µg) (BPA5). 
Interestingly, we found that BPA5 animals 
also exhibited significantly higher pulse fre-
quency than controls: 0.46 ± 0.04 peaks/hour 
for controls, and 0.83 ± 0.10 peaks/hr for 
BPA5 (n = 4; p < 0.05).
Effects of neonatal BPA exposure on 
puberty onset, estrous cycles, pituitary func-
tion, and GnRH pulsatility and signaling in 
adulthood. Early VO is a characteris  tic sign 
of advanced puberty. In rats treated with 
BPA50 and BPA500, VO occurred at ear-
lier ages than in controls (Figure 3): control, 
34.93 ± 0.71 days; BPA50, 32.46 ± 0.71 days; 
and BPA500, 30.15 ± 0.58 days (p < 0.05). 
We found no significant differences in body 
weight among the three groups (Figure 3).
In adulthood, only animals from the 
the BPA500 group showed irregular estrous 
cycles, with high prevalence of estrus after 
PND90, whereas proestrus and diestrus were 
markedly reduced. The percentage of days 
(± SE) in each stage of the cycle for the three 
groups are as follows: control: diestrus = 49.5 
±  0.5%,  proestrus  =  25.0  ±  0.8%, 
estrus = 25.5 ± 1.2%; BPA50: diestrus = 50.8 
± 5.1%, proestrus = 22.7 ± 3.2, estrus = 25.8 
± 2.7; BPA500: diestrus = 0.8 ± 0.8%, 
proestrus = 1.6 ± 0.9%, estrus = 97.7 ± 1.5%; 
(for BPA500 vs. control, p < 0.05). 
We also studied pituitary function 
in adulthood, both in vivo and in vitro and 
GnRH pulsatility ex vivo. For these studies 
we used control and BPA animals in estrus. 
We found no differences in serum gonado-
tropins on the morning of estrus. LH concen-
trations (mean ± SE) were 3.15 ± 0.65 ng/mL 
for control, 4.66 ± 0.41 ng/mL for BPA500, 
and 3.47 ± 0.47 ng/mL for BPA50; FSH 
concentrations were 5.67 ± 0.90 ng/mL for 
control, 6.18 ± 0.55 ng/mL for BPA500, and   
Figure 1. In vivo GnRH-induced LH release in 
PND13 rats. Values shown are mean ± SE serum 
LH in basal (saline) and GnRH-stimulated condi-
tions (after 15 min) in control (n = 11), BPA50 (n = 9), 
and BPA500 (n = 11) treatment groups.
Significance determined by two-way ANOVA: inter  action, 
not significant; main effect chronic treatment, *p < 0.05, 
compared with the corresponding control group.
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Figure 3. Percent of control, BPA50, and BPA500 animals showing VO. Inset: body weights of same animals 
(n = 11–15).
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6.98 ± 0.44 ng/mL for BPA50. As shown in 
Figure 4, 15 min after in vivo GnRH injection, 
serum LH increased in all groups; levels were 
lower in both BPA-treated groups, but this 
attained statistical significance only in high-
dose animals. After 50 min of stimulation, LH 
was still increased, without differences among 
groups. Interestingly, in both the control and 
BPA50 groups at 50 min, LH levels were sig-
nificantly lower than those at 15 min, whereas 
in the BPA500 group, LH levels did not vary 
between these time points.
Regarding GnRH pulsatility, adult animals 
neonatally exposed to either dose of BPA exhib-
ited higher pulse frequency than controls, as 
demonstrated in PND13 females: control, 0.60 
± 0.05 peaks/hr; BPA50, 0.81 ± 0.03 peaks/hr; 
BPA500, 0.83 ± 0.04 peaks/hr (n = 7; control 
vs. BPA50 and BPA500, p < 0.05]. 
In addition, we determined GnRH 
responsiveness in vitro in primary pituitary 
cell cultures. We analyzed LH secretion 
and GnRH-stimulated second messengers. 
Neonatal exposure to BPA dose dependently 
impaired GnRH-induced IP3/inositol com-
pared with controls (Figure 5A). Cells from 
the BPA-treated groups released less basal 
LH than controls; BPA500 also released less 
LH in response to GnRH (Figure 5B). In 
all cases, CRX abolished GnRH-stimulated   
IP3/inositol increase and LH secretion. IP3 
formation and medium LH were highly cor-
related (r = 0.9641; p < 0.005). 
Finally, we analyzed the GnRH-activated 
ERK1/2 pathway in these experimental groups 
(Figure 6A, B). In controls, ERK1/2 phos-
phorylation was rapid (apparent after 5 min 
of GnRH stimulation) and sustained (still 
significantly activated after 30 min), as clas-
sically reported (Liu et al. 2002; Sundaresan 
et al. 1996). In contrast, both BPA groups 
exhibited a rapid but transient activation 
of ERK1/2. In addition, the highest levels 
reached in the BPA500 group were signifi-
cantly lower than levels in controls after 
5 min stimulation. The BPA50 group reached 
the same levels as controls after 5 min stim-
ulation, but a quick significant decrease to 
basal levels occurred thereafter. 
Effects of neonatal exposure to BPA on 
PRL levels in infantile and adult rats. We 
observed no significant differences in serum 
PRL between groups on PND13 (data not 
shown). Nevertheless, serum PRL was signifi-
cantly higher in BPA500 adult animals than 
in controls, and levels in BPA50 animals were 
similar to those in controls [control, 4.34 ± 
0.67 ng/mL (n = 8); BPA50, 5.42 ± 0.66 ng/
mL (n = 7); BPA500, 11.34 ± 1.31 ng/mL 
(n = 8); BPA500 vs. control, p < 0.05].
Discussion
Here we report significant effects of neo-
natal exposure to BPA on the hypothalamic– 
pituitary–  gonadal axis of infantile and adult 
female Sprague-Dawley rats. In 13-day-old 
animals, an age when the pituitary is highly 
sensitive to releasing and inhibiting stimuli, 
neonatal exposure to BPA decreased basal and 
GnRH-stimulated serum LH, and this reached 
statistical significance at the higher dose 
(BPA500). When tested in vitro, BPA500-
treated animals also released less LH, basally 
and after GnRH-stimulation. Interestingly, 
BPA-induced altera  tions in GnRH pulsa-
tility; the three doses of BPA tested in this 
case (BPA5, BPA50, and BPA500) increased 
GnRH pulse frequency, with an increase in the 
number of peaks per hour. Similar effects on 
GnRH pulsatility have been demonstrated by 
estradiol and DDT administration (Matagne 
et al. 2004; Rasier et al. 2007). The decrease 
in basal and GnRH-induced LH release by 
BPA may be the consequence of the increase 
in GnRH pulse frequency, leading to desen-
sitization of the pituitary, as also suggested by 
others (Knobil and Hotchkiss 1988), although 
we cannot exclude some direct effect of BPA 
on LH secretion. 
Neonatal treatment with high and low 
doses of BPA also affected puberty onset, 
dose-dependently advancing VO, without 
affecting body weight. A similar advance in 
puberty onset has also been described after 
a single injection of estradiol on PND10 
(Matagne et al. 2004) or after 5 days of treat-
ment (PND6–PND10) (Rasier et al. 2007). 
Figure 4. In vivo GnRH-induced LH release in adult 
rats in estrus. Values shown are mean ± SE serum 
LH in basal (saline) and GnRH-stimulated condi-
tions (after 15 and 50 min) in control, BPA50, and 
BPA500 treatment groups (n = 7 per group).
Significance determined by two-way repeated measures 
ANOVA: interaction p < 0.05. * p < 0.05 compared with 
control. #p < 0.05 compared with 0 min. ##p < 0.05 com-
pared with 15 min.
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Figure 6. GnRH (1.10–7 M)-induced activation of ERK1/2 [arbitrary units (AU)] in anterior pituitary cell cul-
tures from adult control, BPA50, and BPA500 animals. (A) Representative Western blot of control and 
BPA50 pituitary cells (top) and quantification (bottom). n = 4 per group. (B) Representative Western blot of 
control and BPA500 pituitary cells (top) and quantification (bottom).
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The insecticide DDT, another endocrine 
disruptor, has also been reported to advance 
puberty onset (Rasier et al. 2007). Our results 
show that even though Sprague-Dawley rats 
have been described as possessing a low sen-
sitivity to estrogenic compounds (Steinmetz 
et al. 1997), the effect of BPA, administered 
during a period critical for development, is 
similar to that described after early exposure of 
females to estradiol. Other groups also found 
early VO in animals treated with BPA peri-
natally (from pregnancy through lactation) 
(Durando et al. 2007) or postnatally (Kato 
et al. 2003), this last group using doses twice 
as high as those used in the present study.
Puberty changes occur as a consequence 
of the activation of the hypothalamic– 
pituitary–gonadal axis (Buck Louis et al. 
2008). As discussed above, BPA, as well as 
estradiol and DDT, when administered to 
immature rats, induced acceleration in GnRH 
pulsatility (Rasier et al. 2007). In addition, 
there is physiologically a developmental 
reduction in serum LH before puberty onset 
(Rasier et al. 2007), so the decreased LH lev-
els described above could result from either 
negative feedback, accelerated maturation, or 
both. Therefore, here, we show for the first 
time that BPA could be causing precocious 
hypothalamic–pituitary maturation and thus 
inducing precocious puberty. 
In adults the higher dose significantly dis-
rupted estrous cycles with a high prevalence of 
estrus. Although we found no effect on estrous 
cycles with the lower dose (BPA50), we cannot 
exclude the possibility of loss of cyclicity later 
in life. Durando et al. (2007) and Kato et al. 
(2003) also reported altered estrous cycles, the 
latter with irregular cycles after a single BPA 
dose of 1 mg/animal and persistent estrus after 
a single dose of 4 mg/animal (a dose 8 times 
higher than our BPA500 dose). Similar results 
have also been reported with other xeno-
estrogens, such as the phyto  estrogen coume-
strol (Kouki et al. 2005) and DDT (Rasier 
et al. 2007). 
In the present study, neonatal treat-
ment with BPA did not modify basal serum 
gonado  tropins but did have an impact on the 
in vivo GnRH-induced LH release in adult 
females, with BPA500 reducing the response 
to the decapeptide; to our knowledge, this is 
the first report of such an effect. In addition, 
we also observed accelerated GnRH pulse fre-
quency in adult females neonatally exposed 
to high and low BPA, demonstrating that 
the effect found in infantile animals persists 
throughout life. Moreover, adult pituitary 
cells from animals neo  natally exposed to BPA 
showed decreased basal LH release, but only 
the pituitaries from high-dose animals released 
less LH after GnRH stimulation. When ana-
lyzing signal transduction pathways elicited 
by GnRH, we found that in pituitary cells 
from BPA-treated animals, GnRH-stimulated 
IP3 formation was impaired, showing dose 
dependency for this effect and tightly cor-
relating with LH secretion. This is in agree-
ment with the concept that the IP3–calcium 
pathway is involved in gonadotropin release. 
In contrast, we found that the pattern of 
ERK1/2 activation after GnRH stimulation 
was altered in cultures from both BPA treat-
ment groups. Controls showed the classi-
cal rapid and sustained activation described 
in gonado  tropes (Sundaresan et al. 1996), 
whereas both BPA treatment groups showed 
a peak at 5 min and a subsequent pronounced 
inactivation. The ERK1/2 pathway links sig-
nals from the cell surface to the cytoplasm 
and nucleus; this results in transcriptional 
and mitogenic events. In the case of GnRH-
induced ERK activation, this pathway is 
involved in LHβ (Liu et al. 2002) and GnRH 
receptor expression (Lin and Conn 1999) and 
probably mediates the mitogenic actions of 
GnRH on gonadotropes (Lewy et al. 2003), 
among other actions. High-dose animals 
showed a lower maximal ERK1/2 phophoryla-
tion than the other groups; this is in line with 
the results obtained with IP3, because activa-
tion of ERK1/2 is downstream to PKC activa-
tion (Chamson-Reig et al. 1999; Lewy et al. 
2003; Sundaresan et al. 1996). These results 
show for the first time different intra  cellular 
responses to GnRH in pituitaries from BPA-
treated animals. 
We found no differences in serum PRL 
titers in infantile animals after BPA treat-
ment. In contrast, BPA500 animals showed 
hyper  prolactinemia. These results agree with 
a previous study showing hyper  prolactinemia 
at PND20 and PND30 but not PND15 
(Khurana et al. 2000). Other studies have 
shown hyper  prolactinemia at PND30 in males 
treated prenatally with BPA (Ramos et al. 
2003), whereas others reported an increase in 
serum PRL in adult females ovariectomized and 
treated with BPA (Goloubkova et al. 2000).
Taken together, these results demonstrate 
that exposure to high and low doses of BPA, 
an environmental endocrine disruptor, in a 
period of time critical for development alters 
reproductive parameters in infantile and adult 
animals, causing precocious hypothalamic–
pituitary maturation and precocious puberty, 
altering GnRH pulsatility in infantiles and 
adults, and severely affecting GnRH signal-
ing in the adult pitui  tary. More studies are 
needed, including those with additional doses 
of BPA, to further understand the mechanisms 
underlying these effects.
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